Evidence map›Paper›PMID 26321469›Full record

Trial reportRedox report : communications in free radical research2016

The effect of ubiquinone and combined antioxidant therapy on oxidative stress markers in non-proliferative diabetic retinopathy: A phase IIa, randomized, double-blind, and placebo-controlled study.

Adolfo Daniel Rodríguez-Carrizalez, José Alberto Castellanos-González, Esaú César Martínez-Romero, Guillermo Miller-Arrevillaga, Fermín Paul Pacheco-Moisés, Luis Miguel Román-Pintos, Alejandra Guillermina Miranda-Díaz

3 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Redox report : communications in free radical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03702374 phase3completednot on this mapstarted 2018, after this paper: background citation

Effect of Prolonged Combined Antioxidant Therapy Intake on Oxidative Stress and Mitochondrial Dysfunction Markers in Patients With Diabetic Retinopathy

TypeinterventionalSponsorUniversity of GuadalajaraRan2018 to 2020Enrolled132ConditionsDiabetic RetinopathyArmsCombined antioxidant therapy, Placebo
NCT04071977 phase2completednot on this mapstarted 2020, after this paper: background citation

Effect of Combined Antioxidant Therapy on the Levels of Oxidative Stress Markers in Aqueous and Vitreous Humor of Patients With Proliferative Diabetic Retinopathy

TypeinterventionalSponsorUniversity of GuadalajaraRan2020 to 2021Enrolled40ConditionsDiabetic Retinopathy, Oxidative Stress, DiabetesArmsCombined antioxidant therapy, Placebo
NCT05429229 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Effect of Combined Antioxidant Therapy in Eye Drops on Inflammatory and Oxidative Stress Biomarkers in Tear Film in Patients With Diabetic Retinopathy and Dry Eye Syndrome

TypeinterventionalSponsorAdolfo Daniel Rodriguez-CarrizalezRan2021 to 2024Enrolled78ConditionsDry Eye Syndromes, Diabetic Retinopathy, Oxidative Stress, Tear Film DeficiencyArmsVisuXL®, Lagricel PF®, Humylub PF®
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Research Progress of Coenzyme Q in Diabetes Mellitus and Its Common Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  12. Article
  13. Diabetic retinopathy: emerging concepts of current and potential therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  14. Review
  15. The Role of Citicoline and Coenzyme Q10 in Retinal Pathology.International journal of molecular sciences · 2023
    Review
  16. Coenzyme Q10 and Endocrine Disorders: An Overview.Antioxidants (Basel, Switzerland) · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Adolfo Daniel Rodríguez-Carrizaleza Department of Physiology , Clinical and Experimental Treatment Institute, University Health Sciences Centre, University of Guadalajara,  Mexico (Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología).
José Alberto Castellanos-Gonzálezb Department of Ophthalmology , Specialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute, Mexico (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social).
Esaú César Martínez-Romerob Department of Ophthalmology , Specialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute, Mexico (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social).
Guillermo Miller-Arrevillagab Department of Ophthalmology , Specialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute, Mexico (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social).
Fermín Paul Pacheco-Moisésc University Centre of Exact and Engineering Sciences, University of Guadalajara, Mexico (Centro Universitario de Ciencias Exactas e Ingeniería).
Luis Miguel Román-Pintosa Department of Physiology , Clinical and Experimental Treatment Institute, University Health Sciences Centre, University of Guadalajara,  Mexico (Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología).
Alejandra Guillermina Miranda-Díaza Department of Physiology , Clinical and Experimental Treatment Institute, University Health Sciences Centre, University of Guadalajara,  Mexico (Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología).
Universidad de Guadalajara · MXHospital de Especialidades · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To evaluate the effect of ubiquinone (Coenzyme Q10) and combined antioxidant therapy (CAT) on oxidative stress markers in non-proliferative diabetic retinopathy (NPDR) under clinical management. Study design In a randomized, double-blind, phase IIa, placebo-controlled, clinical trial, three study groups were formed and administered medications as follows: Group 1, Coenzyme Q10; Group 2, CAT; and Group 3, placebo. Methods Serum levels of the products of lipid peroxidation (LPO) and nitrites/nitrates, as markers of oxidative/nitrosative stress, were measured. As antioxidants, the total antioxidant capacity (TAC), catalase activity, and glutathione peroxidase (GPx) activity were measured. Results Baseline serum levels of LPO and nitrites/nitrates were significantly elevated in the three groups vs. healthy group (P < 0.0001), while final levels in the Coenzyme Q10 and CAT groups were decreased vs. normal levels (P < 0.0001). The baseline TAC was consumed in the three groups (P < 0.0001), while final results in the Coenzyme Q10 and CAT groups improved (P < 0.0001). Baseline catalase activity was increased in all groups vs. normal values (P < 0.001), while final levels in the Coenzyme Q10 (P < 0.001) and CAT groups (P < 0.0001) were decreased. GPx behaved similarly to catalase and improved in the final results (P < 0.0001). Discussion Adjunctive antioxidant treatment for 6 months was effective and safe for improving the oxidative stress in NPDR.

Indexed as

AntioxidantsCatalaseDiabetic RetinopathyDouble-Blind MethodFemaleGlutathione PeroxidaseHumansLipid PeroxidationMaleMiddle AgedOxidation-ReductionOxidative StressSuperoxide DismutaseUbiquinoneAntioxidantsCatalasecoenzyme Q10Glutathione PeroxidaseSuperoxide DismutaseUbiquinoneAntioxidantsDiabetes mellitusDiabetic retinopathyNitrosative stressOxidative stress

Identifiers

PMID26321469
PMCPMC8900707
OpenAlexW1943738346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.